1Further improving research quality in cancer management by integration of traditional Chinese medicine and modern medicineSUN Yan1588-1591,16112Targeted therapy for non-small-cell lung cancer using EGFR-TKIsTAN Fen-lai, WANG Yin-xiang, YUAN Xiao-fen, DING Lie-ming, HU Bei, ZHANG Li, ZHOU Jian-ying, SHENG-TU Jian-zhong, SUN Yan1594-16013Pharmacological effects and clinical research of the new drug crizotinib for treating lung cancerWANG Yan, YU Shu-fei1602-16074Consideration of exposure-response relationships during clinical trials of new drugsWEI Min-ji, ZHAO Ming, SHAN Ai-lian1608-16115Comparison of Chinese clinical trial regulation system with relevant international lawYAN Yong-bo, LI Ye1612-1614,16196Application status of small molecule targeted anti-cancer drugs in ChinaCHEN Xiao-yuan, ZHANG Hong, GAO Chen-yan, YANG Zhi-min1615-16197Progress in the study of T cell-dependent antibody responseHUO Yan, AI Wen-chao, Miao Yu-fa, Shen Lian-zhong, LI Bo1620-1623,16728Central composite design optimizes preparation of norcantharidin-loaded chitosan-fibroin microspheres for embolizationZHANG Guang-yu, CHI Mei-yu, NI Jing, CHEN Yuan-lan, SONG Yu-ling, WANG Xiao-qing, ZHANG Xue-nong1624-16309Preparation of lactosyl-norcantharitin phospholipid complex and its pH-sensitive liposomesZHOU Yi, XU Jing-yu, GUAN Min, ZHANG Xue-nong1631-163810Traditional Chinese medicine and cancer:historic deposits and 50-years innovation and developmentLIN Hong-sheng, ZHANG Ying1639-164211Interpretation of drugs for advanced non-small cell lung cancer in 2011XING Pu-yuan, SHI Yuan-kai1643-1646,166612Interpretation of the principles of pharmacotherapy in Chinese Guideline for Renal Cell Carcinoma 2011SHOU Jian-zhong, MA Jian-hui1647-165113Impact of early intervention on chronic CML patients with imatinib failure and the selection of second-generation TKIsZHOU Li1652-165614Progress in imatinib adjuvant therapy of gastrointestinal stromal tumorJIANG Wei-zhong1657-166015Current status of research and development of new tyrosine kinase inhibitorsZHOU Bing-ying, AN Chun-na, PU Xiao-ping1661-166616Advance in research of cyclin-dependent kinase 2 inhibitors based on the structures of target proteinsBAI Xiao-guang, XU Le-xing, LI Yi-liang, WANG Yu-cheng, WANG Ju-xian1667-167217A perspective,open-label,and multi-center phase Ⅱ study of FOLFOX 4 regimen as systemic therapy for patients with unresectable hepatocellular carcinomaGONG Xin-lei, QIN Shu-kui, WANG Ya-jie, XING Bao-cai, WU Qing, CAO Meng-ran, HUA Hai-qing, LIU Xiu-feng1673-167718Tolerability of famitinib malate:the preliminary results from phase Ⅰ clinical trialZHOU Ai-ping, ZHANG Wen, CHANG Chun-xiao, CHI Yi-he-ba-li, WANG Jin-wan1678-1682,169019Phase Ⅰ clinical trial of lyophilized recombinant human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion proteinZHOU Ai-ping, DU Chun-xia, LIU Peng, SUN Yong-kun, WU Guang-moue, ZHU Ping, WANG Jin-wan1683-168720Efficacy of composite matrine injection combined with chemotherapy in the treatment of advanced cancerWEI Ai-fang, ZHANG Fa-en, LAN Chuan, WEI Song, WEI Jin-hua1688-1690 